Novo Nordisk is adjusting to the indicative offer price range for the initial public offering (IPO) of NNIT A/S on Nasdaq Copenhagen as further described in the offering circular, which was published on Feb. 23, 2015.
According to the company, “The adjustment to the initial indicative offer price range reflects higher than expected investor demand for participation in the IPO of NNIT observed during the first days of the book-building process. The offer shares were significantly oversubscribed at the high end of the initial offer price range. Consequently, Novo Nordisk has, as the selling shareholder, decided to increase the indicative offer price range from DKK 100 to DKK 120 per share to DKK 120 to DKK 130 per share.”
Source: Novo Nordisk